Investigation of HEG1, VISTA (VSIR) and PD-L1 expression levels in malignant mesothelioma by immunohistochemical methods and their relationship with histological subtypes

References

• Chan JG-SF, Nicholson AG, Travis WD, et al. Thoracic Tumours. 5th Edition Lyon (France): international Agency for Research on Cancer. Chapter 2, Tumours of the Pleura and pericardium; 2021; p. 193–224.
   Google Scholar
• Pelosi G, Papotti M, Righi L, et al. Pathologic grading of malignant pleural mesothelioma: an Evidence-Based proposal. J Thorac Oncol. 2018;13(11):1–9. doi: 10.1016/j.jtho.2018.07.002.
   Web of Science ®Google Scholar
• Nowak AK, Chansky K, Rice DC, et al. The IASLC mesothelioma staging project: proposals for revisions of the T descriptors in the forthcoming eighth edition of the TNM classification for pleural mesothelioma. J Thorac Oncol. 2016;11(12):2089–2099. doi: 10.1016/j.jtho.2016.08.147.
   PubMedGoogle Scholar
• Chung YS, Kim M, Cha YJ, et al. Expression of V-set immunoregulatory receptor in malignant mesothelioma. Mod Pathol. 2020;33(2):263–270. doi: 10.1038/s41379-019-0328-3.
   PubMed Web of Science ®Google Scholar
• Rrapaj E, Giacometti L, Spina P, et al. Programmed cell death 1 ligand 1 (PD-L1) expression is associated with poor prognosis of malignant pleural mesothelioma patients with good performance status. Pathology. 2021;53(4):462–469. doi: 10.1016/j.pathol.2020.09.018.
   PubMed Web of Science ®Google Scholar
• Muller S, Victoria Lai W, Adusumilli PS, et al. V-domain ıg-containing suppressor of T-cell activation (VISTA), a potentially targetable immune checkpoint molecule, is highly expressed in epithelioid malignant pleural mesothelioma. Mod Pathol. 2020;33(2):303–311. doi: 10.1038/s41379-019-0364-z.
   PubMed Web of Science ®Google Scholar
• Nowak EC, Lines JL, Varn FS, et al. Immunoregulatory functions of VISTA. Immunol Rev. 2017;276(1):66–79. doi: 10.1111/imr.12525.
   PubMed Web of Science ®Google Scholar
• Tsuji S, Washimi K, Kageyama T, et al. HEG1 is a novel mucin-like membrane protein that serves as a diagnostic and therapeutic target for malignant mesothelioma. Sci Rep. 2017;7(1):45768. doi: 10.1038/srep45768.
   PubMedGoogle Scholar
• Matsuura R, Kaji H, Tomioka A, et al. Identification of mesothelioma-specific sialylated epitope recognized with monoclonal antibody SKM9-2 in a mucin-like membrane protein HEG1. Sci Rep. 2018;8(1):14251. doi: 10.1038/s41598-018-32534-8.
   PubMedGoogle Scholar
• Naso JR, Tsuji S, Churg A. HEG1 Is a highly specific and sensitive marker of epithelioid malignant mesothelioma. Am J Surg Pathol. 2020;44(8):1143–1148. doi: 10.1097/PAS.0000000000001469.
   PubMed Web of Science ®Google Scholar
• Hiroshima K, Wu D, Koh E, et al. Membranous HEG1 expression is a useful marker in the differential diagnosis of epithelioid and biphasic malignant mesothelioma versus carcinomas. Pathol Int. 2021;71(9):604–613. doi: 10.1111/pin.13140.
   PubMed Web of Science ®Google Scholar
• Hiroshima K, Wu D, Hamakawa S, et al. HEG1, BAP1, and MTAP are useful in cytologic diagnosis of malignant mesothelioma with effusion. Diagn Cytopathol. 2021;49(5):622–632. doi: 10.1002/dc.24475.
   PubMed Web of Science ®Google Scholar
• Zauderer M, Muller S, Lai W, et al. P2. 06-40 VISTA is highly expressed in malignant pleural mesothelioma (MPM) and ındependent of PD-L1 expression. Poster Sess Present IASLC 19th World Conf Lung Cancer September. 2018;13(10):S758. doi: 10.1016/j.jtho.2018.08.1295.
   Google Scholar
• Moolgavkar SH, Meza R, Turim J. Pleural and peritoneal mesotheliomas in SEER: age effects and temporal trends, 1973-2005. Cancer Causes Control. 2009;20(6):935–944. doi: 10.1007/s10552-009-9328-9.
   PubMed Web of Science ®Google Scholar
• Chekol SS, Sun CC. Malignant mesothelioma of the tunica vaginalis testis: diagnostic studies and differential diagnosis. Arch Pathol Lab Med. 2012;136(1):113–117. doi: 10.5858/arpa.2010-0550-RS.
   PubMed Web of Science ®Google Scholar
• Combaz-Lair C, Galateau-Sallé F, McLeer-Florin A, et al. Immune biomarkers PD-1/PD-L1 and TLR3 in malignant pleural mesotheliomas. Hum Pathol. 2016;52:9–18. doi: 10.1016/j.humpath.2016.01.010.
   PubMed Web of Science ®Google Scholar
• Matsumura E, Kajino K, Abe M, et al. Expression status of PD-L1 and B7-H3 in mesothelioma. Pathol Int. 2020;70(12):999–1008. doi: 10.1111/pin.13028.
   PubMed Web of Science ®Google Scholar
• Kutlar Dursun FS, Alabalik U. Investigation of pd-l1 (cd274), pd-l2 (pdcd1lg2), and ctla-4 expressions in malignant pleural mesothelioma by immunohistochemistry and real-time polymerase chain reaction methods. Pol J Pathol. 2022;73(2):111–119. doi: 10.5114/pjp.2022.119752.
   PubMed Web of Science ®Google Scholar
• Chapel DB, Stewart R, Furtado LV, et al. Tumor PD-L1 expression in malignant pleural and peritoneal mesothelioma by dako PD-L1 22C3 pharmDx and dako PD-L1 28-8 pharmDx assays. Hum Pathol. 2019 May;87:11–17. doi: 10.1016/j.humpath.2019.02.001.
   PubMed Web of Science ®Google Scholar
• Derakhshan F, Ionescu D, Cheung S, et al. Use of programmed death ligand-1 (PD-L1) staining to separate sarcomatoid malignant mesotheliomas From benign mesothelial reactions. Arch Pathol Lab Med. 2020;144(2):185–188. doi: 10.5858/arpa.2019-0370-OA.
   PubMed Web of Science ®Google Scholar
• Kindler H, Karrison T, Tan Y-HC, et al. OA13. 02 phase II trial of pembrolizumab in patients with malignant mesothelioma (MM): interim analysis. J Thor Oncol. 2017;12(1):S293–S294. doi: 10.1016/j.jtho.2016.11.301.
   PubMedGoogle Scholar
• Quispel-Janssen J, van der Noort V, de Vries JF, et al. Programmed death 1 blockade with nivolumab in patients with recurrent malignant pleural mesothelioma. J Thorac Oncol. 2018;13(10):1569–1576. doi: 10.1016/j.jtho.2018.05.038.
   PubMed Web of Science ®Google Scholar
• Le Mercier I, Chen W, Lines JL, et al. VISTA regulates the development of protective antitumor immunity. Cancer Res. 2014;74(7):1933–1944. doi: 10.1158/0008-5472.CAN-13-1506.
   PubMed Web of Science ®Google Scholar
• Villarroel-Espindola F, Yu X, Datar I, et al. Spatially resolved and quantitative analysis of VISTA/PD-1H as a novel immunotherapy target in human non–small cell lung cancer. Clin Cancer Res. 2018;24(7):1562–1573. doi: 10.1158/1078-0432.CCR-17-2542.
   PubMed Web of Science ®Google Scholar